LMT-28
LMT-28 is an orally active and the first synthetic IL-6 inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130[1].
Product Specifications
CAS Number
[1239600-18-0]
UNSPSC
12352005
Target
Interleukin Related
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/lmt-28.html
Purity
98.93
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1OC[C@H](C(C)C)N1C([C@@H](C)[C@H](O)C(CCCCC)=C)=O
Molecular Formula
C17H29NO4
Molecular Weight
311.42
References & Citations
[1]Hong SS, et al. A Novel Small-Molecule Inhibitor Targeting the IL-6 Receptor β Subunit, Glycoprotein 130. J Immunol. 2015 Jul 1;195 (1) :237-45.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IL-6
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Lentiviral mouse Atg9a shRNA (UAS) - Lentiviral mouse Atg9a shRNA (UAS) plasmid
